Alpha Architect US Quantitative Value ETF

Ameriprise Financial Inc. increased its stake in BMS

Stephen T. Higgins, Executive of Freeport-McMoRan Inc., Sells Company's Ordinary Shares

UBS Gives Delta Air Lines a Buy Rating

FactSet Revises Delta Air Lines' 2025 EPS Estimate Down to $5.85

ProPetro's PROPWR unit signs power service contract with Coterra Energy

William Blair Analyst Assigns 'Outperform' Rating to Coterra Energy

FDA grants priority review to Bristol Myers Squibb's Opdivo combination therapy

Wells Fargo Upgrades Bristol Myers Squibb Target Price to $55.00

Humana Grants Six Community Organizations in Oklahoma to Address Health Needs

State Street Corp Increases Stake in Freeport-McMoRan Inc

Bristol Myers Squibb's New Drug Golcadomide Shows Promising Results in Lymphoma Treatment

BMO Begins Coverage and Rates US Airlines

BioNTech SE and Bristol Myers Squibb Report Positive Mid-Stage II Results for Pumitamig in Advanced Triple-Negative Breast Cancer

Northern Mutual Wealth Management Reduced Holdings in Coterra Energy Inc. in Q2

Bristol Myers Squibb to present new lymphoma treatment data at the 67th ASH annual meeting

Delta Air Lines Options Trading Active, Analysts Raise Price Targets

JPMorgan Downgrades APA's Stock Target Price to $26

1832 Asset Management Acquired Delta Air Lines Stocks in Q2

Exane NPB lowers Freeport-McMoRan's target price but maintains an 'outperform' rating

Jefferies Maintains Buy Rating for BMS with a Price Target of $68

AdvisorShares MSOS 2x Daily ETF

cbdMD

Tryhard

Roundhill Cannabis ETF

Neo-Concept

Amplify Seymour Cannabis ETF

AdvisorShares Pure US Cannabis ETF

Canopy Growth

RYTHM

Tilray Brands

Delta Air Lines' stock has risen 15% recently, nearing yearly highs. Analysts debate its valuation, with some seeing it as overvalued at $69.81, while others suggest a fair value of $140.98 based on DCF models. The stock's future depends on travel demand and market conditions. Investors are encouraged to explore further investment opportunities and risks.

Simplywall

Delta Air Lines

Delta Air Lines (DAL): Assessing Valuation After a 15% Share Price Climb and Strong Three-Year Returns

Pomerantz LLP has filed a class action lawsuit against Freeport-McMoran Inc. for alleged securities fraud. The lawsuit follows Freeport's suspension of mining activities at Grasberg Block Cave in Indonesia after a safety incident, which led to a significant drop in stock price. Investors have until January 12, 2026, to join the lawsuit as Lead Plaintiff.

Acceswire

Freeport Mcmoran

Pomerantz LLP Informs Shareholders of Securities Class Action Against Freeport-McMoran Inc – FCX

Top executives at Freeport-McMoRan sold significant shares on December 12, 2025. EVP & CAO Stephen T. Higgins sold 28,423 shares for $1,363,735, and CAO Ellie L. Mikes sold 9,572 shares for $456,201. Despite strong financial health and positive technical momentum, valuation concerns and operational risks remain. FCX is rated Neutral by TipRanks' AI Analyst, Spark.

Tip Ranks

Top Executives Cash In on Freeport-McMoRan Stock!

Stephen T. Higgins, EVP & CAO of Freeport-McMoRan Inc., reported the sale of common shares of the company. The full filing is available via EDGAR, the SEC's system.

Reuters

Freeport-McMoRan EVP & CAO Stephen T. Higgins Reports Sale of Common Shares

Delta Air Lines Inc. stock fell 1.06% to $69.81 on Friday, underperforming compared to competitors. Southwest Airlines rose 1.06%, United Airlines fell 1.43%, and American Airlines remained unchanged. Delta's stock snapped a four-day winning streak and closed 1.28% below its 52-week high. Trading volume was below the 50-day average.

Dow Jones

Delta Air Lines Inc. Stock Underperforms Friday When Compared To Competitors

Freeport-McMoRan (FCX) faces class action lawsuits over safety issues at its Grasberg mine, impacting its stock valuation. Despite legal challenges, the stock has seen a 17.1% rise in the past month. Analysts debate whether FCX is undervalued, with a fair value of $48.52 against a current price of $48.11. The company plans brownfield expansions to boost copper supply, but operational uncertainties and policy shifts in Indonesia pose risks. The stock's high earnings multiple suggests potential downside if sentiment changes.

Freeport-McMoRan (FCX): Reassessing Valuation After Grasberg Safety Lawsuits and Class Action Deadlines

Is Carnival Corporation Stock Underperforming the Nasdaq?

Barchart Option

Carnival

Is Carnival Corporation Stock Underperforming the Nasdaq?

Elevance Health highlights the evolving role of health plans in supporting members through various health situations, including cancer, mental health, and pregnancy. By simplifying healthcare, improving care coordination, and leveraging data-driven insights, Elevance Health aims to provide personalized care and better health outcomes. The company emphasizes a whole-health approach, integrating physical, behavioral, and social factors. Programs like expanded doula care and the Community Pharmacy Total Care (CPTC) program exemplify this approach, helping members navigate healthcare with confidence and improving overall health outcomes.

StockTitan

Elevance Health

Elevance Health Reflects On The Changed Role of Health Plans | ELV Stock News

ABVX

The upcoming week will see corporate earnings releases for companies in the STOXX 600 index, including Abivax SA on December 15, 2025, and Carnival PLC on December 19, 2025. The earnings will be announced either after market close (AMC) or before market opens (BMO). EPS estimates are not provided in the diary but can be accessed through Workspace.

Abivax SA

DIARY-Europe's STOXX 600 corporate earnings week ahead

AM Best has affirmed and upgraded various credit ratings for Elevance Health, Inc. and its subsidiaries, including Anthem Health and Wellpoint entities. The ratings reflect strong balance sheet strength, favorable operating performance, and strategic importance within the organization. Anthem Health's financial leverage is expected to decline, and Elevance has been active in acquisitions. Despite challenges in some business lines, Anthem Health's operating performance remains strong with consistent premium growth and solid earnings. The outlook for these ratings is stable.

AM Best Takes Various Credit Rating Actions on Elevance Health, Inc. and Most of Its Subsidiaries | ELV Stock News

Pomerantz LLP has filed a class action lawsuit against Freeport-McMoran Inc. for alleged securities fraud and unlawful business practices. The lawsuit follows incidents at Freeport's Grasberg Block Cave operation in Indonesia, where mining activities were suspended after a blockage trapped seven workers, resulting in two fatalities and five missing workers. The news led to significant drops in Freeport's stock price. Shareholders have until January 12, 2026, to join the lawsuit.

Pomerantz LLP Informs Shareholders of Class Action Filing Against Freeport-McMoran Inc. – FCX

ORCL

HOOD

WELL

INTC

Visa(V) rose 6.11%, with a trading turnover 4.4 Billion USD, and a year-to-date rose 10.1%. Newmont(NEM) rose 5.32%, with a trading turnover 1.1 Billion USD, and a year-to-date rose 171.6%. Oracle(ORCL) fell 10.83%, with a trading turnover 19.4 Billion USD, and a year-to-date rose 20.5%. Robinhood(HOOD) fell 9.05%, with a trading turnover 5.5 Billion USD, and a year-to-date rose 231.1%.

- The Nasdaq Composite Index fell by 0.25%, with a year-to-date increase of 22.2%.  
- The S&P 500 Index rose by 0.21%, accumulating a 17.3% gain for the year, while the Dow Jones increased by 1.34%, with a 14.5% year-to-date rise.  
- Notable stock movements include Visa rising by 6.11% and Newmont Mining increasing by 5.32%, while Oracle and Robinhood saw declines of 10.83% and 9.05%, respectively.

Top Gainers & Losers

Visa

Newmont

Constellation Energy

Mastercard

Progressive

Oracle

Robinhood

Welltower Op

Intel

Top 5 US Stock Gainers/Losers (>100B) (12.11)

Humana Inc. shares rose 3.83% to $266.49, outperforming competitors on a strong trading day. The S&P 500 Index increased by 0.21% and the Dow Jones by 1.34%. This marks the second consecutive day of gains for Humana, though it remains 15.49% below its 52-week high. Trading volume was higher than the 50-day average.

Humana

Humana Inc. Stock Outperforms Competitors On Strong Trading Day

CTSH

Michael Patsalos-Fox, Director of Cognizant Technology Solutions Corp, filed a Form 144 with the SEC to sell 25,000 shares on December 11, 2025, through Morgan Stanley Smith Barney LLC, under a prearranged trading plan (10b5-1).

Cognizant Tech Solutions

Dir Patsalos-Fox Files To Sell 25,000 Of Cognizant Technology Solutions Corp [CTSH]